Wang, H., Ashton, R., Hensel, J. A., Lee, J. H., Khattar, V., Wang, Y., . . . Ponnazhagan, S. (2020). RANKL-targeted combination therapy with osteoprotegerin variant devoid of TRAIL binding exerts biphasic effects on skeletal remodeling and antitumor immunity. Mol Cancer Ther.
Chicago Style CitationWang, Hong, Reading Ashton, Jonathan A. Hensel, Joo Hyoung Lee, Vinayak Khattar, Yong Wang, Jessy S. Deshane, i Selvarangan Ponnazhagan. "RANKL-targeted Combination Therapy With Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects On Skeletal Remodeling and Antitumor Immunity." Mol Cancer Ther 2020.
Cita MLAWang, Hong, et al. "RANKL-targeted Combination Therapy With Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects On Skeletal Remodeling and Antitumor Immunity." Mol Cancer Ther 2020.